When should norethindrone be used instead of medroxyprogesterone acetate, and what are the differences in indications, dosing, and side effects?

Norethindrone vs Medroxyprogesterone Acetate: Clinical Selection Guide

Norethindrone (particularly norethindrone acetate at therapeutic doses ≥5 mg daily) should be used instead of medroxyprogesterone acetate when treating endometriosis-related pain, abnormal uterine bleeding, or in patients with contraindications to higher thrombotic risk, while depot medroxyprogesterone acetate (DMPA) remains the preferred injectable contraceptive with the option for patient self-administration. 1, 2

Primary Indications Where Norethindrone Is Preferred

Endometriosis Pain Management

• Norethindrone acetate 5 mg daily is a first-line hormonal therapy for endometriosis-related dysmenorrhea, non-cyclical pelvic pain, and dyspareunia, providing pain relief equivalent to more expensive GnRH-agonist protocols. 1
• Norethindrone acetate demonstrates statistically significant improvement in pain scores compared with placebo in randomized trials. 1
• When combined oral contraceptives are contraindicated (due to smoking ≥35 years, migraine with aura, hypertension with end-organ damage, diabetes with vascular complications, or history of venous thromboembolism), the recommendation shifts specifically to norethindrone acetate 5 mg daily or a levonorgestrel-releasing IUD as safer alternatives. 1

Abnormal Uterine Bleeding

• Norethindrone has pronounced effects on the endometrium, making it superior for treating abnormal uterine bleeding, endometriosis, and endometrial hyperplasia compared to other progestogens. 3
• For prolonged bleeding in etonogestrel implant users, norethindrone acetate 10 mg daily effectively stops bleeding in 86.7% of patients within 7 days, compared to 48.9% with placebo. 4
• Patients with obesity or heavy menstrual bleeding may require higher doses of norethindrone acetate to achieve menstrual suppression. 5

Thrombotic Risk Considerations

• Current use of norethindrone acetate at higher therapeutic doses (not the 0.35 mg contraceptive dose) is associated with increased odds of venous thromboembolism (adjusted OR 3.00), while low-dose oral norethindrone showed reduced odds of VTE compared to nonuse. 6
• Medroxyprogesterone acetate (oral form) carries an adjusted OR of 1.98 for VTE, and DMPA has an adjusted OR of 2.37. 6
• The VTE risk appears dose-dependent: contraceptive-dose norethindrone (0.35 mg) carries no increased risk, but therapeutic doses may increase risk. 3

Primary Indications Where Medroxyprogesterone Acetate Is Preferred

Injectable Contraception

• DMPA (depot medroxyprogesterone acetate) is the established injectable contraceptive, with subcutaneous DMPA-SC now recommended to be made available for self-administration as it improves continuation rates while maintaining equivalent pregnancy rates, side effects, and adverse events compared to provider administration. 2
• DMPA use is most common in younger women (aged 15–24 years), non-Hispanic Black women, and women with lower income. 2
• Provider-administered DMPA should remain available alongside self-administered options. 2

Endometriosis (Alternative First-Line)

• Depot medroxyprogesterone acetate provides comparable pain relief to combined oral contraceptives and is considered an effective first-line option for endometriosis pain. 1
• However, norethindrone acetate is often preferred due to its more pronounced endometrial effects and potentially lower thrombotic risk profile at contraceptive doses. 3, 6

Dosing Differences

Norethindrone

• Contraceptive dose: 0.35 mg daily, taken continuously at the same time every day with no interruption between pill packs. 7
• Therapeutic dose for endometriosis: norethindrone acetate 5 mg daily. 1
• For prolonged bleeding (implant users): norethindrone acetate 10 mg daily until bleeding stops for 2 consecutive days or 30 days maximum. 4

Medroxyprogesterone Acetate

• Injectable (DMPA): 150 mg intramuscularly every 3 months or subcutaneous formulation for self-administration. 2
• Oral medroxyprogesterone acetate is NOT recommended for secondary amenorrhea or dysfunctional uterine bleeding due to its prolonged action and difficulty predicting withdrawal bleeding timing. 8
• For advanced carcinoma (palliative): 400-1000 mg weekly initially, potentially maintained at 400 mg monthly. 8

Side Effect Profile Differences

Bleeding Patterns

• Continuous combined hormone therapy with conjugated estrogen plus medroxyprogesterone acetate results in fewer bleeding days and shorter time to amenorrhea compared to estradiol plus norethindrone acetate. 9
• In postmenopausal hormone replacement, medroxyprogesterone acetate provides better bleeding control than norethindrone acetate. 9, 10
• However, for DMPA users experiencing breakthrough bleeding, NSAIDs for 5-7 days are the recommended treatment. 11

Mood Effects

• In women WITHOUT a history of premenstrual syndrome, medroxyprogesterone acetate induces less negative mood and more positive mood symptoms than norethindrone during hormone replacement therapy. 12
• Women WITH a history of premenstrual syndrome respond strongly (negatively) to both progestogens. 12

Physical Symptoms

• Medroxyprogesterone acetate causes more physical symptoms (bloating, breast tenderness) than norethindrone in both groups. 12

Bone and Cardiovascular Effects

• Norethindrone has beneficial effects on bone mineral density and positive or neutral effects on cardiovascular health. 3

Cancer Risk

• Long-term norethindrone use is associated with a slightly increased breast cancer risk. 3

Critical Clinical Decision Algorithm

Step 1: Determine primary indication

• If injectable contraception needed → DMPA (offer self-administration option) 2
• If endometriosis pain → Norethindrone acetate 5 mg daily (especially if estrogen contraindicated) 1
• If abnormal uterine bleeding → Norethindrone acetate (superior endometrial effects) 3

Step 2: Assess thrombotic risk factors

• If patient has migraine with aura, age ≥35 with smoking, hypertension with complications, diabetes with vascular disease, or prior VTE → Avoid therapeutic-dose norethindrone acetate; use low-dose norethindrone 0.35 mg or LNG-IUD instead 1, 6
• If using therapeutic doses of either agent, counsel on VTE risk (higher with norethindrone acetate > DMPA > oral medroxyprogesterone) 6

Step 3: Consider patient-specific factors

• If history of premenstrual syndrome → Both agents may worsen mood; medroxyprogesterone slightly better for mood 12
• If obesity or heavy bleeding → May require higher norethindrone acetate doses for suppression 5
• If postmenopausal and bleeding control is priority → Medroxyprogesterone acetate achieves amenorrhea faster 9

Important Caveats

• Norethindrone partially converts to ethinylestradiol: 10-20 mg norethindrone corresponds to 20-30 µg ethinylestradiol, which is clinically significant for thrombotic risk and migraine considerations. 3
• The 0.35 mg contraceptive dose of norethindrone does NOT carry increased VTE risk, but therapeutic doses (≥5 mg) do. 6, 3
• Neither hormonal therapy eradicates endometriotic lesions, and neither adversely affects future fertility potential. 1
• If first-line progestin therapy fails after 3-6 months for endometriosis, escalate to GnRH agonist for at least 3 months with add-back therapy. 1